Concord Biotech Ltd (NSE: CONCORDBIO, BSE: 543960) is an Ahmedabad, Gujarat-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹12,495 Cr, it ranks #528 by market cap among the 6,197 Indian listed companies on FinBizNet, and #8 of 11 in Pharmaceutical CDMO and CRO Services. At ₹595.00 (as of 16 Nov 2026), the share price is 26.3% below its 52-week high of ₹807.50 and 20.6% above its 52-week low of ₹493.50. The share price is down 14.8% over one year and down 18.3% over three months.
| Current Price | ₹595.00 |
|---|---|
| Market Cap | ₹12,495 Cr |
| NSE Symbol | CONCORDBIO |
| BSE Code | 543960 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 24.2 |
| Return on Equity | 13.54% |
| Return on Assets | 8.91% |
| 52-Week Range | ₹493.50 – ₹807.50 |
| 1-Year Price Change | -14.8% |
| 3-Month Price Change | -18.3% |
| Beta (1Y) | 0.13 |
| Dividend Yield | 0.63% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.concordbiotech.com |
| Revenue | ₹309 Cr |
|---|---|
| Net Profit | ₹70 Cr |
| Net Margin | 22.5% |
| EPS (Basic) | ₹6.65 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Concord Biotech Ltd reported revenue of ₹309 Cr in Q2 FY27, up 25.1% from ₹247 Cr in Q2 FY26 and up 20.0% from ₹257 Cr in Q1 FY27. It posted a net profit of ₹70 Cr for the quarter, against a net profit of ₹63 Cr in Q2 FY26 (up 10.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹204 Cr (Q1 FY26) to ₹430 Cr (Q4 FY25). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹309 Cr | ₹70 Cr | 22.5% |
| Q1 FY27 | ₹257 Cr | ₹58 Cr | 22.4% |
| Q4 FY26 | ₹326 Cr | ₹88 Cr | 27.1% |
| Q3 FY26 | ₹278 Cr | ₹64 Cr | 22.9% |
| Q2 FY26 | ₹247 Cr | ₹63 Cr | 25.5% |
| Q1 FY26 | ₹204 Cr | ₹44 Cr | 21.6% |
| Q4 FY25 | ₹430 Cr | ₹140 Cr | 32.7% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 44.09% of Concord Biotech Ltd's shares as of Sept 2026, against 44.08% in Sept 2025 (+0.01 percentage points). Delivery averaged 40.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomyci
1. Manufacturing and trading in pharmaceutical products-This segment engages in researching, developing, manufacturing, marketing, and selling pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Manufacturing and trading in pharmaceutical products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +71.9% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.5% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +120.3% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -9.4% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -35.2% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -27.9% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -14.5% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -14.8% |
| Blue Jet Healthcare Ltd | ₹10,140 Cr | 38 | 19.88% | ₹376 Cr | -9.8% |
Listed by market capitalisation. Ratios are shown for context only.
Concord Biotech Ltd is trading at ₹595.00, with a market capitalisation of ₹12,495 Cr.
Concord Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Concord Biotech Ltd has a P/E of 24.2 and a return on equity of 13.54%.
Concord Biotech Ltd is listed on the NSE under the symbol CONCORDBIO and on the BSE under the scrip code 543960.
Concord Biotech Ltd's share price is down 14.8% over one year and down 18.3% over three months. Its 52-week range is ₹493.50 to ₹807.50.
In Q2 FY27, Concord Biotech Ltd reported revenue of ₹309 Cr and net profit of ₹70 Cr, with basic EPS of ₹6.65 (consolidated, parsed from the company's exchange filing).
Concord Biotech Ltd reported revenue of ₹309 Cr in Q2 FY27, up 25.1% from ₹247 Cr in Q2 FY26 and up 20.0% from ₹257 Cr in Q1 FY27.
Promoters held 44.09% of Concord Biotech Ltd's shares as of Sept 2026, against 44.08% in Sept 2025 (+0.01 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.